Current antimalarial therapy heavily relies on artemisinins, a drug class that only targets the blood stages of the parasite and which is increasingly feared to elicit drug resistance. Flannery, Chatterjee and Winzeler discuss the approaches used to develop novel drugs that are active against different life cycle stages with the ultimate aim of eliminating malaria.
- Erika L. Flannery
- Arnab K. Chatterjee
- Elizabeth A. Winzeler
